Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DONQ52 in Celiac Disease (LILY Study)
NCT05425446Phase 1Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Sep 2022
- Primary completion
- Aug 2024
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of DONQ52 in celiac disease, sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoints: Incidence and severity of treatment-emergent adverse events up to 246 days, Safety as assessed by Vital signs up to 246 days and 2 more. Started Sep 2022; status: completed.
02
Drugs
DONQ52
03
Conditions
celiac disease
Beyond the preview
Go deeper on NCT05425446.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05425446.